| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mobility Limitation | 22 | 2025 | 222 | 3.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2018 | 1523 | 2.280 |
Why?
|
| Hypoglycemic Agents | 16 | 2016 | 200 | 2.240 |
Why?
|
| Anxiety Disorders | 8 | 2020 | 81 | 2.030 |
Why?
|
| Exercise | 26 | 2024 | 701 | 1.960 |
Why?
|
| Aged | 125 | 2025 | 11022 | 1.910 |
Why?
|
| Aging | 23 | 2025 | 1010 | 1.910 |
Why?
|
| Hypoglycemia | 11 | 2018 | 45 | 1.840 |
Why?
|
| Telephone | 5 | 2017 | 67 | 1.570 |
Why?
|
| Aged, 80 and over | 69 | 2025 | 4157 | 1.490 |
Why?
|
| Life Style | 19 | 2020 | 418 | 1.480 |
Why?
|
| Female | 128 | 2025 | 21532 | 1.350 |
Why?
|
| Male | 125 | 2025 | 20740 | 1.340 |
Why?
|
| Disabled Persons | 12 | 2023 | 101 | 1.330 |
Why?
|
| Walking | 17 | 2020 | 217 | 1.320 |
Why?
|
| Disability Evaluation | 21 | 2019 | 262 | 1.200 |
Why?
|
| Humans | 145 | 2025 | 34562 | 1.170 |
Why?
|
| Cognition | 18 | 2025 | 576 | 1.130 |
Why?
|
| Geriatric Assessment | 19 | 2019 | 369 | 1.080 |
Why?
|
| Activities of Daily Living | 13 | 2022 | 267 | 1.000 |
Why?
|
| Brain | 11 | 2025 | 1032 | 0.910 |
Why?
|
| Diabetic Angiopathies | 6 | 2013 | 153 | 0.890 |
Why?
|
| Gait | 7 | 2023 | 134 | 0.840 |
Why?
|
| Quality of Life | 10 | 2023 | 1032 | 0.830 |
Why?
|
| Obesity | 14 | 2025 | 1246 | 0.820 |
Why?
|
| Middle Aged | 54 | 2025 | 12726 | 0.770 |
Why?
|
| Exercise Therapy | 10 | 2018 | 283 | 0.750 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2025 | 1393 | 0.740 |
Why?
|
| Weight Loss | 10 | 2025 | 494 | 0.720 |
Why?
|
| Resistance Training | 7 | 2024 | 84 | 0.720 |
Why?
|
| Health Education | 16 | 2018 | 170 | 0.720 |
Why?
|
| Rural Population | 4 | 2017 | 297 | 0.700 |
Why?
|
| Blood Glucose | 11 | 2018 | 529 | 0.680 |
Why?
|
| Independent Living | 9 | 2025 | 95 | 0.670 |
Why?
|
| Contrast Sensitivity | 3 | 2025 | 6 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2025 | 565 | 0.630 |
Why?
|
| Muscle Strength | 10 | 2024 | 157 | 0.620 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2018 | 28 | 0.610 |
Why?
|
| Caloric Restriction | 5 | 2025 | 122 | 0.600 |
Why?
|
| Accidental Falls | 4 | 2020 | 116 | 0.590 |
Why?
|
| Health Status | 7 | 2023 | 411 | 0.580 |
Why?
|
| Pilot Projects | 18 | 2025 | 585 | 0.570 |
Why?
|
| Single-Blind Method | 17 | 2020 | 214 | 0.570 |
Why?
|
| Hyperglycemia | 3 | 2016 | 88 | 0.570 |
Why?
|
| Physical Fitness | 8 | 2019 | 135 | 0.540 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2016 | 55 | 0.540 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 17 | 0.520 |
Why?
|
| Cognition Disorders | 8 | 2017 | 390 | 0.520 |
Why?
|
| Depression | 7 | 2017 | 458 | 0.490 |
Why?
|
| Motor Activity | 8 | 2018 | 356 | 0.490 |
Why?
|
| Cardiovascular Diseases | 13 | 2017 | 1209 | 0.470 |
Why?
|
| Postural Balance | 7 | 2024 | 152 | 0.460 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 1607 | 0.460 |
Why?
|
| Body Composition | 10 | 2025 | 415 | 0.450 |
Why?
|
| Risk Factors | 21 | 2020 | 4137 | 0.450 |
Why?
|
| Vision Disorders | 2 | 2025 | 25 | 0.450 |
Why?
|
| Mental Health Services | 1 | 2015 | 36 | 0.440 |
Why?
|
| Long-Term Care | 3 | 2019 | 24 | 0.440 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 515 | 0.420 |
Why?
|
| Treatment Outcome | 18 | 2022 | 3623 | 0.420 |
Why?
|
| Telemedicine | 1 | 2015 | 120 | 0.410 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 177 | 0.390 |
Why?
|
| Hospitalization | 8 | 2022 | 500 | 0.390 |
Why?
|
| Body Mass Index | 13 | 2024 | 954 | 0.380 |
Why?
|
| Diabetic Nephropathies | 6 | 2013 | 228 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2018 | 274 | 0.370 |
Why?
|
| Thiazolidinediones | 4 | 2013 | 51 | 0.350 |
Why?
|
| Age Factors | 10 | 2019 | 1262 | 0.350 |
Why?
|
| Longitudinal Studies | 9 | 2025 | 803 | 0.340 |
Why?
|
| Health Promotion | 6 | 2017 | 264 | 0.340 |
Why?
|
| Insulin | 4 | 2018 | 394 | 0.330 |
Why?
|
| Risk Assessment | 5 | 2020 | 1508 | 0.330 |
Why?
|
| Yoga | 2 | 2022 | 53 | 0.330 |
Why?
|
| United States | 17 | 2019 | 4278 | 0.310 |
Why?
|
| Rotator Cuff | 4 | 2018 | 77 | 0.300 |
Why?
|
| Patient Selection | 2 | 2025 | 291 | 0.300 |
Why?
|
| Muscle, Skeletal | 5 | 2015 | 575 | 0.300 |
Why?
|
| Overweight | 5 | 2025 | 289 | 0.290 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 2367 | 0.290 |
Why?
|
| Medicare | 3 | 2019 | 224 | 0.290 |
Why?
|
| Arthralgia | 1 | 2008 | 33 | 0.280 |
Why?
|
| Anxiety | 4 | 2022 | 206 | 0.280 |
Why?
|
| Interleukin-6 | 3 | 2019 | 258 | 0.280 |
Why?
|
| Health Expenditures | 2 | 2018 | 71 | 0.270 |
Why?
|
| Critical Illness | 2 | 2019 | 89 | 0.270 |
Why?
|
| Hospitals | 2 | 2018 | 105 | 0.270 |
Why?
|
| Adult | 20 | 2024 | 10030 | 0.270 |
Why?
|
| Knee Joint | 1 | 2008 | 151 | 0.260 |
Why?
|
| Research Design | 8 | 2025 | 337 | 0.250 |
Why?
|
| Nerve Net | 2 | 2025 | 141 | 0.250 |
Why?
|
| Movement | 2 | 2016 | 63 | 0.250 |
Why?
|
| Antihypertensive Agents | 5 | 2017 | 379 | 0.250 |
Why?
|
| Shoulder Joint | 3 | 2018 | 141 | 0.240 |
Why?
|
| Pain | 4 | 2022 | 330 | 0.240 |
Why?
|
| Patient Compliance | 3 | 2018 | 218 | 0.240 |
Why?
|
| Motor Skills Disorders | 2 | 2017 | 7 | 0.240 |
Why?
|
| Frail Elderly | 2 | 2018 | 73 | 0.240 |
Why?
|
| Hand Strength | 5 | 2018 | 106 | 0.230 |
Why?
|
| Vestibular Diseases | 1 | 2005 | 2 | 0.230 |
Why?
|
| Vision, Binocular | 1 | 2025 | 2 | 0.230 |
Why?
|
| Alzheimer Disease | 2 | 2025 | 295 | 0.230 |
Why?
|
| Posture | 1 | 2005 | 63 | 0.220 |
Why?
|
| Physical Examination | 1 | 2005 | 94 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2005 | 53 | 0.220 |
Why?
|
| Energy Intake | 1 | 2025 | 138 | 0.210 |
Why?
|
| Social Support | 2 | 2016 | 195 | 0.210 |
Why?
|
| Feeding Behavior | 1 | 2025 | 168 | 0.210 |
Why?
|
| Hypertension | 7 | 2017 | 1024 | 0.200 |
Why?
|
| Neuropsychological Tests | 8 | 2017 | 372 | 0.200 |
Why?
|
| Muscles | 1 | 2023 | 69 | 0.200 |
Why?
|
| Macular Degeneration | 1 | 2023 | 27 | 0.200 |
Why?
|
| Leukoencephalopathies | 1 | 2023 | 12 | 0.190 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 145 | 0.190 |
Why?
|
| Wrist | 1 | 2022 | 51 | 0.190 |
Why?
|
| Fee-for-Service Plans | 2 | 2019 | 14 | 0.190 |
Why?
|
| Cohort Studies | 9 | 2025 | 1910 | 0.190 |
Why?
|
| Mortality | 2 | 2015 | 127 | 0.180 |
Why?
|
| Inflammation | 3 | 2018 | 557 | 0.180 |
Why?
|
| Losartan | 2 | 2019 | 68 | 0.180 |
Why?
|
| Attitude | 1 | 2002 | 43 | 0.180 |
Why?
|
| Ankle | 1 | 2002 | 32 | 0.180 |
Why?
|
| Knee | 1 | 2002 | 31 | 0.180 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 922 | 0.180 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 72 | 0.180 |
Why?
|
| Visual Acuity | 4 | 2025 | 76 | 0.180 |
Why?
|
| Patient Transfer | 2 | 2019 | 43 | 0.180 |
Why?
|
| Upper Extremity | 2 | 2012 | 69 | 0.170 |
Why?
|
| Osteoarthritis | 1 | 2002 | 80 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2025 | 2463 | 0.170 |
Why?
|
| Adipose Tissue | 2 | 2015 | 366 | 0.170 |
Why?
|
| Linear Models | 7 | 2019 | 465 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2022 | 157 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2020 | 20 | 0.160 |
Why?
|
| Comorbidity | 5 | 2017 | 596 | 0.160 |
Why?
|
| Coronary Artery Disease | 4 | 2013 | 441 | 0.150 |
Why?
|
| Subacute Care | 1 | 2019 | 18 | 0.150 |
Why?
|
| Time Factors | 8 | 2025 | 2353 | 0.150 |
Why?
|
| Disease Progression | 8 | 2014 | 634 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 70 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2019 | 70 | 0.150 |
Why?
|
| Palliative Care | 1 | 2019 | 52 | 0.150 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 13 | 0.140 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 804 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2018 | 17 | 0.140 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 7 | 0.140 |
Why?
|
| Baltimore | 1 | 2018 | 50 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2010 | 154 | 0.140 |
Why?
|
| Kidney | 3 | 2011 | 528 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 105 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2018 | 80 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2018 | 256 | 0.130 |
Why?
|
| Osteoarthritis, Knee | 3 | 2003 | 96 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 112 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 103 | 0.130 |
Why?
|
| Prevalence | 3 | 2015 | 1034 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 168 | 0.130 |
Why?
|
| Diet, Reducing | 3 | 2016 | 109 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 96 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 230 | 0.130 |
Why?
|
| Fibroblasts | 3 | 2009 | 122 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 1435 | 0.120 |
Why?
|
| Mechanical Phenomena | 1 | 2016 | 29 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 248 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2015 | 20 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2016 | 39 | 0.120 |
Why?
|
| Factor Analysis, Statistical | 3 | 2010 | 79 | 0.120 |
Why?
|
| Double-Blind Method | 5 | 2019 | 597 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 75 | 0.110 |
Why?
|
| Sleep | 1 | 2016 | 90 | 0.110 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 77 | 0.110 |
Why?
|
| Shoulder | 1 | 2015 | 51 | 0.110 |
Why?
|
| Blood Pressure | 3 | 2014 | 901 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 40 | 0.110 |
Why?
|
| Skin | 3 | 2009 | 224 | 0.110 |
Why?
|
| Memory | 2 | 2014 | 216 | 0.110 |
Why?
|
| Prognosis | 5 | 2019 | 1606 | 0.110 |
Why?
|
| Isometric Contraction | 2 | 2012 | 28 | 0.110 |
Why?
|
| Health Surveys | 1 | 2015 | 202 | 0.110 |
Why?
|
| Atrophy | 1 | 2014 | 51 | 0.110 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2014 | 2 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 372 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2015 | 141 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 302 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2015 | 161 | 0.100 |
Why?
|
| Pyruvaldehyde | 1 | 2013 | 1 | 0.100 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 116 | 0.100 |
Why?
|
| Vitamin K 1 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Organ Size | 4 | 2017 | 236 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 74 | 0.100 |
Why?
|
| Physical Endurance | 2 | 2014 | 42 | 0.100 |
Why?
|
| Exercise Tolerance | 3 | 2010 | 140 | 0.100 |
Why?
|
| Health Behavior | 3 | 2014 | 246 | 0.090 |
Why?
|
| Lipids | 1 | 2014 | 267 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2013 | 180 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 198 | 0.090 |
Why?
|
| Age Distribution | 2 | 2017 | 211 | 0.090 |
Why?
|
| Lower Extremity | 2 | 2016 | 106 | 0.090 |
Why?
|
| Calcium | 1 | 2013 | 343 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 439 | 0.080 |
Why?
|
| Acceleration | 2 | 2022 | 75 | 0.080 |
Why?
|
| Aviation | 1 | 2010 | 2 | 0.080 |
Why?
|
| Pennsylvania | 1 | 2010 | 85 | 0.080 |
Why?
|
| Range of Motion, Articular | 3 | 2016 | 209 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 89 | 0.080 |
Why?
|
| Macular Edema | 1 | 2010 | 17 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 2831 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 939 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 187 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 120 | 0.080 |
Why?
|
| Cells | 1 | 2009 | 5 | 0.070 |
Why?
|
| Leg | 1 | 2009 | 71 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3825 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 1290 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 106 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 83 | 0.070 |
Why?
|
| Markov Chains | 1 | 2008 | 32 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2019 | 155 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2014 | 1176 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 108 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 22 | 0.070 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 28 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 3805 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2006 | 545 | 0.060 |
Why?
|
| Child | 3 | 2024 | 2614 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2013 | 837 | 0.060 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 10 | 0.060 |
Why?
|
| Catalase | 1 | 2006 | 16 | 0.060 |
Why?
|
| Siblings | 1 | 2006 | 24 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 703 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 928 | 0.060 |
Why?
|
| Health Status Indicators | 2 | 2020 | 75 | 0.060 |
Why?
|
| Sex Factors | 2 | 2019 | 708 | 0.060 |
Why?
|
| Antioxidants | 1 | 2006 | 126 | 0.060 |
Why?
|
| Logistic Models | 2 | 2011 | 808 | 0.060 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 18 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2007 | 240 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2009 | 439 | 0.060 |
Why?
|
| tau Proteins | 1 | 2025 | 40 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2017 | 194 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 245 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 123 | 0.050 |
Why?
|
| Creatinine | 2 | 2017 | 206 | 0.050 |
Why?
|
| Attention | 1 | 2024 | 91 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 315 | 0.050 |
Why?
|
| Hip | 1 | 2022 | 17 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 926 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 614 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 86 | 0.050 |
Why?
|
| Amlodipine | 1 | 2002 | 15 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 67 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2002 | 9 | 0.050 |
Why?
|
| Joints | 2 | 2012 | 12 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 54 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2002 | 52 | 0.050 |
Why?
|
| Weight Lifting | 1 | 2002 | 9 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2002 | 28 | 0.050 |
Why?
|
| Emotions | 1 | 2002 | 60 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 90 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 76 | 0.040 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 129 | 0.040 |
Why?
|
| Albuminuria | 2 | 2017 | 181 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 318 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2002 | 239 | 0.040 |
Why?
|
| Sarcopenia | 2 | 2012 | 67 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2009 | 823 | 0.040 |
Why?
|
| Probability | 2 | 2009 | 168 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 26 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 257 | 0.030 |
Why?
|
| Respiratory Function Tests | 2 | 2010 | 105 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 190 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 32 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 79 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2009 | 310 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 85 | 0.030 |
Why?
|
| Pulse | 1 | 2016 | 11 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 53 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 40 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 185 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 261 | 0.030 |
Why?
|
| Time | 1 | 2016 | 29 | 0.030 |
Why?
|
| Rotation | 1 | 2016 | 54 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2016 | 107 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 89 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 247 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.030 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2015 | 17 | 0.030 |
Why?
|
| C-Peptide | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 185 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 72 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 52 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2014 | 22 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 79 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 42 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 889 | 0.030 |
Why?
|
| Glomerular Basement Membrane | 1 | 2013 | 4 | 0.030 |
Why?
|
| Methionine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 755 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 33 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 325 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2014 | 367 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 544 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 115 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 446 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 260 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 99 | 0.020 |
Why?
|
| Muscle Stretching Exercises | 1 | 2012 | 5 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 188 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 193 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2013 | 199 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 95 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cystatin C | 1 | 2011 | 33 | 0.020 |
Why?
|
| Intention | 1 | 2011 | 31 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 47 | 0.020 |
Why?
|
| Choristoma | 1 | 2011 | 18 | 0.020 |
Why?
|
| Thigh | 1 | 2011 | 43 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2011 | 55 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 561 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2011 | 52 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2013 | 483 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 144 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 52 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 326 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 97 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 432 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 61 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 305 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 24 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2009 | 34 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 480 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 175 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 508 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 343 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 41 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 170 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 363 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 227 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 248 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 341 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 112 | 0.020 |
Why?
|
| Psychometrics | 1 | 2008 | 143 | 0.020 |
Why?
|
| Risk Management | 1 | 2007 | 23 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 988 | 0.010 |
Why?
|
| Stroke | 1 | 2011 | 700 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2006 | 169 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 269 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 744 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 323 | 0.010 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Glomerular Mesangium | 1 | 2002 | 2 | 0.010 |
Why?
|
| Thrombospondin 1 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 10 | 0.010 |
Why?
|
| Proteinuria | 1 | 2002 | 55 | 0.010 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2002 | 57 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2002 | 15 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 265 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 149 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 2002 | 30 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2002 | 168 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 385 | 0.010 |
Why?
|